Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
PLoS One. 2012;7(9):e45475. doi: 10.1371/journal.pone.0045475. Epub 2012 Sep 18.
Glioblastoma (GBM) is the most common malignant primary brain tumors in adults and exhibit striking aggressiveness. Although GBM constitute a single histological entity, they exhibit considerable variability in biological behavior, resulting in significant differences in terms of prognosis and response to treatment. In an attempt to better understand the biology of GBM, many groups have performed high-scale profiling studies based on gene or protein expression. These studies have revealed the existence of several GBM subtypes. Although there remains to be a clear consensus, two to four major subtypes have been identified. Interestingly, these different subtypes are associated with both differential prognoses and responses to therapy. In the present study, we investigated an alternative immunohistochemistry (IHC)-based approach to achieve a molecular classification for GBM. For this purpose, a cohort of 100 surgical GBM samples was retrospectively evaluated by immunohistochemical analysis of EGFR, PDGFRA and p53. The quantitative analysis of these immunostainings allowed us to identify the following two GBM subtypes: the "Classical-like" (CL) subtype, characterized by EGFR-positive and p53- and PDGFRA-negative staining and the "Proneural-like" (PNL) subtype, characterized by p53- and/or PDGFRA-positive staining. This classification represents an independent prognostic factor in terms of overall survival compared to age, extent of resection and adjuvant treatment, with a significantly longer survival associated with the PNL subtype. Moreover, these two GBM subtypes exhibited different responses to chemotherapy. The addition of temozolomide to conventional radiotherapy significantly improved the survival of patients belonging to the CL subtype, but it did not affect the survival of patients belonging to the PNL subtype. We have thus shown that it is possible to differentiate between different clinically relevant subtypes of GBM by using IHC-based profiling, a method that is advantageous in its ease of daily implementation and in large-scale clinical application.
胶质母细胞瘤(GBM)是成人中最常见的恶性原发性脑肿瘤,表现出明显的侵袭性。尽管 GBM 构成单一的组织学实体,但它们在生物学行为上表现出相当大的可变性,导致预后和对治疗的反应存在显著差异。为了更好地了解 GBM 的生物学特性,许多研究小组已经基于基因或蛋白质表达进行了大规模的分析研究。这些研究揭示了 GBM 存在几种亚型。尽管尚未达成明确共识,但已经确定了两到四种主要亚型。有趣的是,这些不同的亚型与不同的预后和对治疗的反应相关。在本研究中,我们研究了一种替代的免疫组织化学(IHC)方法,以实现 GBM 的分子分类。为此,我们通过 EGFR、PDGFRA 和 p53 的免疫组织化学分析对 100 例手术 GBM 样本进行了回顾性评估。这些免疫染色的定量分析使我们能够识别以下两种 GBM 亚型:“经典样”(CL)亚型,其特征是 EGFR 阳性和 p53-和 PDGFRA-阴性染色;“神经前体细胞样”(PNL)亚型,其特征是 p53-和/或 PDGFRA 阳性染色。与年龄、切除范围和辅助治疗相比,这种分类在总体生存方面是一个独立的预后因素,与 PNL 亚型相关的生存时间明显更长。此外,这两种 GBM 亚型对化疗的反应不同。替莫唑胺联合常规放疗显著改善了属于 CL 亚型的患者的生存,但对属于 PNL 亚型的患者的生存没有影响。因此,我们已经表明,通过使用基于 IHC 的分析,可以区分不同的具有临床意义的 GBM 亚型,这种方法在日常实施的便利性和大规模临床应用方面具有优势。